NanoVibronix, Inc.(NAOV)Earnings, Financials & Key Ratios

NAOV•NASDAQ

$1.90

Price updated May 29, 2026

SectorHealthcare IndustryMedical Devices Sub-IndustryAesthetics, dermatology, and wound care

AboutNanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.Show more

Revenue$3M-0.2%
EBITDA-$23M-539.2%
Net Income-$18M-390.8%
EPS (Diluted)-28.93-110.7%
Gross Margin5.99%-89.8%
EBITDA Margin-896.55%-540.4%
Operating Margin-896.55%-540.3%
Net Margin-712.3%-391.8%
ROE-106.58%+33.6%

NAOV Price & Volume

NanoVibronix, Inc. (NAOV) stock price & volume — 10-year historical chart

Loading chart...

Persistent Operational Deficits Threaten Long-Term Solvency

Investment Thesis • Updated 2026Q1

VerdictNegative

Growth:Contracting

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Unsustainable cash burn rate

Key Thesis Takeaways

NanoVibronix faces a precarious outlook characterized by stalled revenue growth and structural margin erosion, as evidenced by the collapse of gross margins to -8.4% in 2026Q1.
The company's reliance on intangible assets, with $29.1M in goodwill dominating a $39.9M asset base, suggests significant valuation risk.
Investors should remain cautious as the firm continues to burn cash at an unsustainable rate, with operating expenses like the $3.3M SG&A in 2025Q4 consistently dwarfing top-line revenue.

Verdict Logic

the company's net margin of -51.4% in 2025Q4 and the rapid depletion of cash reserves suggest a high probability of future dilutive financing to sustain operations.

NAOV Growth Metrics

NanoVibronix, Inc. (NAOV) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years33.04%

5 Years32.59%

3 Years50.29%

TTM-18.07%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM-247.68%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM-82.72%

Return on Capital

10 Years-169.97%

5 Years-109.86%

3 Years-119.15%

Last Year-129.42%

Peers Comparison

Key metrics vs top competitors for NanoVibronix, Inc. (NAOV)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
NAOVNanoVibronix, Inc.Current	$1.90	$512.71K	-0.14	-0.2%	-712.3%	-106.58%	—
ARAYAccuray Incorporated	$0.25	$29.63M	-16.07	2.68%	-10.76%	-77.48%	—
LNTHLantheus Holdings, Inc.	$103.41	$6.73B	30.33	0.5%	18.05%	24.33%	—
STIMNeuronetics, Inc.	$1.35	$93.94M	-2.29	99.17%	-24.48%	-139.83%	—
NSPRInspireMD, Inc.	$0.72	$33.62M	-0.94	28.11%	-344.13%	-81.52%	—
GKOSGlaukos Corporation	$150.65	$8.82B	-45.93	32.33%	-34.34%	-26.46%	—